Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company.

It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.

The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors.

Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.